Hjem › Eggstokkreft › Colorado › Denver
Kliniske studier for Eggstokkreft i Denver, CO
16 studier for Eggstokkreft søker deltakere på steder i og rundt Denver (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Kaiser Permanente-Franklin, Denver
A Study of PHST001 in Advanced Solid Tumors
RekruttererFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- Sarah Cannon Research Institute at HealthOne, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- Rocky Mountain Cancer Center, Denver
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- SCRI at HealthOne, Denver
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
RekruttererFase 1
- Sarah Cannon Research Institute at HealthONE /ID# 278785, Denver
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruttererFase 3
- AdventHealth Medical Group - Porter, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
RekruttererFase 1/2
- SCRI at HCA Health One, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RekruttererFase 1
- Sarah Cannon Research Institute - Denver DDU, Denver
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruttererFase 1
- Normunity Investigational Site, Denver
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruttererFase 3
- Cancer Center of Colorado at Sloan's Lake, Denver
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
RekruttererFase 1/2
- Research Site, Denver
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
RekruttererFase 1
- Sarah Cannon Research Institute at HealthONE, Denver
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RekruttererFase 1
- Dren Investigational Site, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Denver
Eggstokkreft-studier i andre byer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
Andre studier i Denver
- Metastatisk kreft29 studier
- Brystkreft29 studier
- Ikke-småcellet lungekreft27 studier
- Multipelt myelom27 studier
- Kolorektal kreft23 studier
- Melanom19 studier
- Prostatakreft19 studier
- Kreft (alle typer)18 studier
- Lungekreft16 studier
- Endometriekreft15 studier
- Non-Hodgkins lymfom14 studier
- Pankreaskreft13 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.